Intersect ENT Inc (XENT) Given Average Recommendation of “Buy” by Analysts

Intersect ENT Inc (NASDAQ:XENT) has been given a consensus recommendation of “Buy” by the fourteen ratings firms that are presently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $33.43.

Several equities research analysts recently issued reports on XENT shares. BidaskClub upgraded Intersect ENT from a “sell” rating to a “hold” rating in a report on Thursday, January 25th. Northland Securities reiterated a “hold” rating and issued a $25.00 price objective on shares of Intersect ENT in a report on Friday, November 3rd. JPMorgan Chase & Co. upgraded Intersect ENT from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Zacks Investment Research cut Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $36.00 price objective on shares of Intersect ENT in a report on Monday, December 11th.

In other Intersect ENT news, COO Richard E. Kaufman sold 958 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $37.21, for a total value of $35,647.18. Following the transaction, the chief operating officer now directly owns 87,512 shares of the company’s stock, valued at approximately $3,256,321.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Lisa D. Earnhardt sold 10,685 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $31.87, for a total transaction of $340,530.95. Following the completion of the transaction, the insider now directly owns 487,868 shares in the company, valued at $15,548,353.16. The disclosure for this sale can be found here. Insiders sold a total of 178,210 shares of company stock worth $5,819,188 over the last three months. Corporate insiders own 13.70% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XENT. FMR LLC lifted its stake in Intersect ENT by 247.7% in the 2nd quarter. FMR LLC now owns 1,482,909 shares of the medical equipment provider’s stock worth $41,447,000 after purchasing an additional 1,056,389 shares in the last quarter. Jennison Associates LLC lifted its stake in Intersect ENT by 22.4% in the 4th quarter. Jennison Associates LLC now owns 2,036,202 shares of the medical equipment provider’s stock worth $65,973,000 after purchasing an additional 372,320 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in Intersect ENT in the 2nd quarter worth approximately $9,384,000. State Street Corp lifted its stake in Intersect ENT by 33.6% in the 2nd quarter. State Street Corp now owns 552,344 shares of the medical equipment provider’s stock worth $15,437,000 after purchasing an additional 138,968 shares in the last quarter. Finally, OxFORD Asset Management LLP purchased a new position in Intersect ENT in the 3rd quarter worth approximately $2,371,000. 87.69% of the stock is currently owned by institutional investors and hedge funds.

Shares of Intersect ENT (NASDAQ XENT) opened at $35.15 on Friday. Intersect ENT has a twelve month low of $12.50 and a twelve month high of $37.90. The stock has a market capitalization of $1,040.00, a PE ratio of -56.69 and a beta of 0.78.

COPYRIGHT VIOLATION NOTICE: “Intersect ENT Inc (XENT) Given Average Recommendation of “Buy” by Analysts” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/09/intersect-ent-inc-xent-given-average-recommendation-of-buy-by-analysts.html.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply